A new risk score to assess atrial fibrillation risk in hypertensive patients (ESCARVAL-RISK Project)

Domingo Orozco-Beltran1, Jose A. Quesada1, Vicente Bertomeu-Gonzalez2,3,4, Jose M. Lobos-Bejarano5,12, Jorge Navarro-Perez6,7, Vicente F. Gil-Guillen1, Luis Garcia Ortíz9, Adriana Lopez-Pineda1*, Angel Castellanos-Rodriguez10, Angela Lopez-Domenech1, Antonio Francisco J. Cardona-Llorens11 & Concepcion Carratala-Munuera1

This study aimed to assess atrial fibrillation (AF) incidence and predictive factors in hypertensive patients and to formulate an AF risk assessment score that can be used to identify the patients most likely to develop AF. This was a cohort study of patients recruited in primary healthcare centers. Patients aged 40 years or older with hypertension, free of AF and with no previous cardiovascular events were included. Patients attended annual visits according to clinical practice until the end of study or onset of AF. The association between AF incidence and explanatory variables (age, sex, body mass index, medical history and other) was analyzed. Finally, 12,206 patients were included (52.6% men, and mean age was 64.9 years); the mean follow-up was 36.7 months, and 394 (3.2%) patients were diagnosed with AF. The incidence of AF was 10.5/1000 person-years. Age (hazard ratio [HR] 1.06 per year; 95% confidence interval [CI] 1.05–1.08), male sex (HR 1.88; 95% CI 1.53–2.31), obesity (HR 2.57; 95% CI 1.70–3.90), and heart failure (HR 2.44; 95% CI 1.45–4.11) were independent predictors (p < 0.001). We propose a risk score based on significant predictors, which enables the identification of people with hypertension who are at the greatest risk of AF.

Data from the World Health Organization (WHO) show that 33.5 million people worldwide— or 0.5% of the world’s population—had atrial fibrillation (AF) in 2013, with higher prevalence detected in industrialized countries1. Indeed, in Europe and the United States, different studies have estimated a prevalence of 1% to 3%, depending on the population assessed and their age2,3. The demographic burden of AF is rising dramatically worldwide due to population ageing and probably to an increase in risk factors, particularly the obesity-diabetes pairing4,5.

In clinical practice, recognizing arrhythmia may be difficult, particularly in its subclinical and paroxysmal forms; these challenges explain a large part of the current underdiagnosis5. Often, AF is diagnosed incidentally in asymptomatic patients or in those with non-specific symptoms6. Previous studies have identified certain factors associated with a greater risk of developing AF7,8, opening the door to earlier detection through close monitoring of these patients. The Framingham Heart Study9 has reinforced prior knowledge of individual risk factors for AF, which include age, sex, body mass index (BMI), blood pressure variables, and prevalent cardiovascular disease. Moreover, that study and others9,10 have highlighted the role of obesity in AF, either as an independent precursor to AF or as a determinant linked to other more important risk factors such as type 2 diabetes and arterial

1Chair of Family Medicine, Clinical Medicine Department, Miguel Hernandez University of Elche, San Juan de Alicante, Spain. 2Cardiology Department, University Hospital of San Juan de Alicante, San Juan de Alicante, Spain. 3Clinical Medicine Department, Miguel Hernandez University, San Juan de Alicante, Spain. 4CIBER Cardiovascular CB16/11/00420, Madrid, Spain. 5Jazmin Primary Care Health Center, Madrid, Spain. 6Department of Internal Medicine, Valencia Clinical Hospital, Valencia, Spain. 7INCLIVA Research Institute, Valencia, Spain. 8Department of Medicine, University of Valencia, Valencia, Spain. 9Cardiovascular Research Group of Castilla y León, Health Center La Alamedilla de Salamanca, Salamanca, Spain. Research Network in Preventive Activities and Health Promotion (REDIAPP). Department of Biomedical and Diagnostic Sciences, University of Salamanca, Salamanca, Spain. 10Ciudad Periodistas Primary Care Health Center, Madrid, Spain. 11Pathology and Surgery Department, Miguel Hernandez University of Elche, San Juan de Alicante, Spain. 12Jose M. Lobos-Bejarano is deceased. *email: adriannalp@hotmail.com
hypertension. Other predictive factors include alterations detected during basal 12-lead electrocardiography (for example, P wave duration, PR interval or high density supraventricular extrasystolia) and echocardiography (for instance, left atrial dilatation)\(^9\).

AF is closely related to arterial hypertension, considered its main causal factor\(^11\) primarily because of its high prevalence\(^12\). Previous reports have observed that at least 75% of patients with AF who are attended in primary care are hypertensive\(^4\). Left ventricle hypertrophy and left atrial enlargement and remodeling are common underlying physiopathological features. Improved community control of hypertension has contributed to decreasing age-adjusted mortality for ischemic stroke\(^13\); however, hypertension and AF, alone or together, continue being the main risk factors for stroke\(^14\).

The ischemic strokes that are related to AF (at least one in four) are the most lethal, debilitating and costly in terms of social and healthcare resources.\(^4\) Paradoxically, these cardioembolic events are more amenable to preventive anticoagulant therapy than those not associated with AF\(^15\), with meta-analyses showing reductions of up to 64%\(^16\). Moreover, AF may be responsible for a high proportion of cryptogenic stroke, which presents challenges for detecting arrhythmia and requires advanced diagnostic tools\(^17\). Thus, identifying predictors for AF and patients at risk could improve prevention of arrhythmia (for example, through behavioral modifications, blood pressure control, and—where appropriate—treatment with inhibitors of the renin-angiotensin-aldosterone system [RAAS]\(^18,19\)).

Investigators involved in the Framingham Heart Study\(^9\), the Atherosclerosis Risk In Communities (ARIC) study\(^20\), and the Cohorts for Aging and Research in Genomic Epidemiology (CHARGE)-AF study\(^21\)—all population-based cohort studies—have developed scoring systems for AF risk assessment, but none of these have been validated in people with hypertension despite this being the main risk factor for the disease\(^11\). Our prospective study aims to assess AF incidence and predictive factors in a cohort of hypertensive patients included in the ESCARVAL-RISK study (EStudio CARdiometabolico VALenciano)\(^22\) and to formulate an AF risk assessment scale that can be used in clinical practice to accurately identify the patients most likely to develop AF.

Methods

Study participants. This is an observational cohort study of patients who were consecutively recruited from January 1, 2007 to December 31, 2010 in public primary healthcare centers of the region of Valencia (population 4,980,689 according to the 2015 census), run by the Valencian Health Agency, with a public health system where all population has free access to primary or secondary care.

Inclusion criteria were: residents of the region of Valencia, with available medical records in the Electronic Record System (ABUCASIS); free of AF; aged 40 years or older; diagnosed with hypertension; and with no previous cardiovascular events who attended a primary healthcare center for routine visits (ESCARVAL-RISK cohort\(^22\)). Diagnosis of hypertension was according to the following criteria: systolic blood pressure of at least 140 mmHg or diastolic blood pressure of at least 90 mmHg, as documented in two separate and consecutive readings; diagnosis according to ICD code 401.9; or receiving any medication for blood pressure. We excluded patients with any type of AF known prior to study commencement, history of high or moderate alcohol consumption, short life expectancy, or any other diseases, like hyperthyroidism and severe chronic obstructive pulmonary disease (COPD), that the attending physician believed could skew study results. Other mental or social factors that could present challenges for follow-up were also exclusion criteria, as was the unavailability of valid indicators for the analysis variables. Patients who presented a cardiovascular event during follow up were not excluded. Our inclusion criteria, study variables, and methodology have been published in detail elsewhere\(^22\).

The Committee for Ethics and Clinical Trials (CEIC in its Spanish abbreviation) of the Center for Public Health and Public Health Research (DGSP-CSISP in its Spanish abbreviation) approved the study protocol, and participants provided written informed consent. The repository of data is not available. The study was performed in accordance with relevant guidelines and regulations.

Study variables. Our response variable was the appearance (yes/no) of AF. Explanatory variables were age; sex; body mass index (BMI: normal, <25 kg/m\(^2\); overweight, 25–30 kg/m\(^2\); grade I obesity, 30–35 kg/m\(^2\); and grade II obesity, >35 kg/m\(^2\)); tobacco use (non-smoker/smoker or ex-smoker); history of diabetes mellitus (yes/no) and/or dyslipidemia (yes/no), onset of ischemic heart disease (IHD) (yes/no), stroke (yes/no), and/or congestive heart failure (CHF) (yes/no) during follow-up; treatment with antihypertensive therapy (yes/no) or for diabetes (yes/no), dyslipidemia (yes/no), and/or hypertension (yes/no); and analytical variables like systolic and diastolic blood pressure, fasting glucose levels, total cholesterol, high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol, triglycerides, serum creatinine, and estimated glomerular filtration rate (eGFR) as calculated with the CKD-EPI creatinine equation\(^23\).

Follow-up. At the initial visit, physicians collected data on study variables. Thereafter, participants attended annual visits to undergo a thorough examination for AF; follow-up checks continued until the end of study or onset of AF. In addition, all patients with symptoms were further studied in the cardiology departments, including by echocardiography and ambulatory electrocardiography monitoring. Diagnosis was based on electrocardiographic readings according to the criteria of the European Society of Cardiology\(^24\) and documented in the participant's medical record (ICD-code 427.3).

Statistical analysis. We performed a bivariate analysis to test the association between AF incidence and the qualitative explanatory variables using contingency tables, calculating the P value with the chi-square test of association. For quantitative variables, we determined the minimum, maximum, mean, and standard deviation, and we compared the mean value according to presence/absence of AF using the student's t-test. We adjusted the estimated risk of AF using the Cox proportional hazards model, estimating the hazard ratio (HR) and its 95%
confidence interval (CI). We employed backward selection of variables according to the Akaike information criterion (AIC) and verified the fit of the model using the likelihood ratio test (LRT), then estimating the C-index and its 95% CI as a measure of prediction. We analyzed the possible interactions between variables and tested the Cox proportional hazards assumption. The c-index with 95% confidence intervals was calculated using 10-fold cross-validation (repeated 30 times and averaged). Finally, we formulated a table of risks and probabilities of developing AF over three years, using the optimal model based on the points system described by Sullivan et al. in 2004. For statistical analyses, we used SPSS software (version 18.0) and the R package (version 3.2.3).

**Results**

Our final sample size included 12,206 participants; 52.6% were men, and mean age was 64.9 years (range 40 to 94). Longest follow-up was 47 months (mean 36.7).

Table 1 shows the incidence of AF at study end, according to qualitative indicators (chi-square test). AF: atrial fibrillation; BMI: body mass index; BP: blood pressure; IHD: ischemic heart disease; CHF: congestive heart failure. *Statistically significant (P < 0.05).

| Participant characteristics | Total | No AF | Yes AF | P value |
|----------------------------|-------|-------|-------|---------|
| Age                        |       |       |       |         |
| <60 years                  | 3636  | 29.8  | 3596  | 98.9    | 40     | 1.1 | <0.001* |
| 60–74 years                | 6280  | 51.5  | 6065  | 96.6    | 215    | 3.4 |
| ≥75 years                  | 2290  | 18.8  | 2151  | 93.9    | 139    | 6.1 |
| Sex                        |       |       |       |         |
| Men                        | 6416  | 52.6  | 6168  | 96.1    | 248    | 3.9 | <0.001* |
| Women                      | 5790  | 47.4  | 5644  | 97.5    | 146    | 2.5 |
| BMI                        |       |       |       |         |
| Normal <25 kg/m²           | 1278  | 10.5  | 1247  | 97.6    | 31     | 2.4 | 0.002* |
| Overweight 25–30 kg/m²     | 5050  | 41.4  | 4896  | 97.0    | 154    | 3.0 |
| Grade I obesity, 30–35 kg/m²| 4091 | 33.5  | 3965  | 96.9    | 126    | 3.1 |
| Grade II obesity >35 kg/m² | 1787  | 14.6  | 1704  | 95.4    | 83     | 4.6 |
| Smoking                    |       |       |       |         |
| Non-smoker                 | 6880  | 56.4  | 6658  | 96.8    | 222    | 3.2 | 0.993 |
| Smoker/ex-smoker           | 5326  | 43.6  | 5154  | 96.8    | 172    | 3.2 |
| Diabetes mellitus          |       |       |       |         |
| No                         | 8399  | 68.8  | 8158  | 97.1    | 241    | 2.9 | 0.001* |
| Yes                        | 3807  | 31.2  | 3654  | 96.0    | 153    | 4.0 |
| Dyslipidemia               |       |       |       |         |
| No                         | 6999  | 57.3  | 6767  | 96.7    | 232    | 3.3 | 0.529 |
| Yes                        | 5207  | 42.7  | 5045  | 96.9    | 162    | 3.1 |
| IHD                        |       |       |       |         |
| No                         | 11628 | 95.3  | 11271 | 96.9    | 357    | 3.1 | <0.001* |
| Yes                        | 578   | 4.7   | 541   | 93.6    | 37     | 6.4 |
| Stroke                     |       |       |       |         |
| No                         | 11931 | 97.7  | 11552 | 96.8    | 379    | 3.2 | 0.035* |
| Yes                        | 275   | 2.3   | 260   | 94.5    | 15     | 5.5 |
| CHF                        |       |       |       |         |
| No                         | 12067 | 98.9  | 11688 | 99.6    | 379    | 3.1 | <0.001* |
| Yes                        | 139   | 1.1   | 124   | 89.2    | 15     | 10.8 |
| BP treatment               |       |       |       |         |
| No                         | 7462  | 61.1  | 7233  | 96.9    | 229    | 3.1 | 0.212 |
| Yes                        | 4744  | 38.9  | 4579  | 96.5    | 165    | 3.5 |

Table 1. Incidence of AF at study end, according to qualitative indicators (chi-square test). AF: atrial fibrillation; BMI: body mass index; BP: blood pressure; IHD: ischemic heart disease; CHF: congestive heart failure.

**Discussion**

**Main findings.** We observed a mean incidence of 10.5 cases of AF per 1000 person-years in hypertensive patients over the age of 40, with more cases appearing in men than in women. The multivariate Cox regression model showed that significant predictors for AF include age, male gender, BMI, and CHF. Based on these findings and indicators, we developed a three-year risk score for incident AF in a prospective, population-based cohort with hypertension.
Comparison with other studies. The incidence of AF in this hypertensive study cohort was higher than that reported at 10 years in the general population in the Framingham Heart Study (6.3 per 1000 age-adjusted person-years in men and 3.3 per 1000 age-adjusted person-years in women)\(^9\). Previous studies in Europe\(^26,27\), also in the general population, have likewise observed lower incidence rates than in our study. However, other authors have noted that the risk of developing AF is significantly higher in people with hypertension compared to people with normal blood pressure\(^28\). In 2482 hypertensive patients with a mean age of 51 years and no initial pharmacological treatment, Verdecchia et al.\(^19\) found an AF rate of 4.6 per 1000 person-years. In contrast, Alvez-Cabratosa et al.\(^29\) observed an incidence rate that is more consistent with ours, of 12.5 per 1000 person-years in hypertensive patients.
patients in Spain. With regard to incidence by age group and sex, our results are concordant with those published elsewhere: incidence is higher in men than in women and increases with age.

In addition, and similarly to previous studies, we found several qualitative and quantitative variables associated with the appearance of AF. In line with other studies over the past decade, obesity stands out as a major independent predictor, with grade II obesity conferring a similar level of AF risk as CHF. However, CHF is not always an etiological factor in AF, as the causal pathway between the two conditions goes in both directions.

They often share underlying features constituting the causal mechanism, such as hypertension and ischemic heart disease, whose optimal medical treatment can prevent or delay the appearance of both arrhythmia and CHF.

Obesity is attracting increased attention as a risk factor for AF, based on epidemiological, physiopathological, and clinical evidence. Obesity is associated with diastolic dysfunction; a systemic proinflammatory state; atrial dilatation; and the presence of metabolically active pericardial adipose tissue, which produces arrhythmogenesis. Moreover, obesity is closely linked to other cardiometabolic risk factors (diabetes, dyslipidemia, and hypertension) and to other well-known determinants of AF (e.g., obstructive sleep apnea). In the OFRECE study, the presence of obesity and central obesity increased the likelihood of developing AF more than any other cardiometabolic risk factor. Unlike other predictors, obesity is also a modifiable risk factor, as reported by Abed et al. and Pathak et al. Thus, in people with AF, non-pharmacological interventions to reduce weight and waist circumference (basically modifications of diet and physical activity), together with optimal treatment for cardiometabolic risk factors, can lead to proportional reductions in the severity of symptoms and the necessity to use antiarrhythmic drugs. The LEGACY study in Australia followed 355 patients with paroxysmal or persistent AF and a BMI of 27 kg/m² or more (78% were hypertensive) for five years; investigators found that reducing baseline body weight by 10% or more was associated with a six-fold greater probability of arrhythmia-free survival.
Other studies have reported that antihypertensive treatment can reduce the risk of AF in people with hypertension\(^{35,36}\); however, our results did not confirm this finding, probably because the study took place in the context of routine clinical practice. In this setting, clinical inertia and lack of therapeutic adherence are commonplace\(^{37}\), and in our population there was a high proportion of patients not being treated for hypertension despite their medical records showing high blood pressure—either because they had not received a diagnosis for hypertension or because their clinician had only recommended behavioral modifications, with a more dubious potential impact.

Finally, our proposed risk score showed an acceptable predictive capacity (C-index = 0.69), although lower than those obtained in the original cohorts from the general population of Framingham\(^{9}\) or ARIC\(^{20}\), both yielding a C-index of 0.78; or the more recent CHARGE-AF model\(^{21}\) (C-index = 0.77). However, the C-index in these studies has tended to decrease when used in external populations; for example, the C-index for the Framingham risk score was 0.68 when validated in the ARIC study population. All these scores have been developed in American cohorts, which have proven very different from Mediterranean patients. Furthermore, all of these scoring systems use a greater number of variables than we do; the CHARGE-AF model considers age, race, height, weight, systolic and diastolic blood pressure, current smoking, use of antihypertensive medication, diabetes, and history of myocardial infarction and CHF.

**Strengths and limitations.** There are few predictive risk scores for AF and to our knowledge, this is the only one that specifically focuses on patients with hypertension. However, readers should consider the results of this observational study in light of the advantages and limitations of registry-based data. On the one hand, electronic health records provide quick and low-cost access to rich longitudinal data on large populations for epidemiologic research. Moreover, registry data are a good reflection of real clinical practice. On the other hand, there is also a greater chance of AF not being properly recorded in routine clinical practice. In order to validate the correct interpretation of electrocardiogram by physicians, an audit was performed in 10% of patients with AF at the end of the study, i.e. we checked the electrocardiogram results in 10% of patients with AF, and 100% were correct. Regarding the variables collected, sleep apnea, physical inactivity and high-intensity exercise increase AF risk; however, these variables are not routinely recorded in medical history by primary care physicians, so we could not include them in the study analysis. The echocardiography is also of great value to predict atrial fibrillation in individuals, but it is not a good variable to include in a risk score due to its low availability. Another potential limitation is that our risk score is derived from a single, predominantly white Mediterranean hypertensive cohort. Some authors have reported that the most commonly used risk scores, like Framingham, overestimate high risk in Mediterranean populations\(^{38}\), potentially leading to many overtreated patients. Thus, further research in needed to validate the findings in a different cohort.

**Implications.** Researchers and clinicians have always valued the simplicity of a risk score for clinical practice, even at the expense of accuracy. However, nowadays all medical histories are electronic, so it is possible to achieve a more elaborate and accurate risk score without sacrificing ease of use. Furthermore, other AF risk scores have not been validated in a Mediterranean population. Further research is needed to compare the predictive capacity of our risk score versus other AF risk scores in this context. The present study demonstrates that a few simple indicators—easily obtained in clinical examination, like age, sex, BMI and history of CHF—are independently associated with a higher incidence of AF in a Mediterranean population. Clinicians may consider these predictors during the consultation and perform simple follow-up of hypertensive patients in clinical practice: (i) facilitating early detection of AF through opportunistic screening, pulse measurement, and eventually electrocardiogram,

| Score | Estimated risk |
|-------|--------------|
| ≤ 0   | <0.5%        |
| 1     | 0.7%         |
| 2     | 1.0%         |
| 3     | 1.3%         |
| 4     | 1.8%         |
| 5     | 2.5%         |
| 6     | 3.3%         |
| 7     | 4.5%         |
| 8     | 6.1%         |
| 9     | 8.3%         |
| 10    | 11.1%        |
| 11    | 14.8%        |
| 12    | 19.6%        |
| 13    | 25.7%        |
| 14    | 33.3%        |
| 15    | 42.4%        |
| 16    | 52.8%        |

Table 5. Probability of developing atrial fibrillation within three years, according to risk score.
through 24-hour electrocardiographic (Holter) monitoring or even through pulse monitoring using wearable health devices; (ii) intensifying the control of blood pressure; (iii) enabling the preferential use of medications that can delay the appearance of arrhythmia (RAAS inhibitors); and (iv) intervening energetically to modify behaviors, particularly sedentarism and obesity. Finally, the proposed risk score could entail improvements in the prevention and early detection of AF in the hypertensive population. All these improvement strategies should be validated in studies specifically designed for this purpose.

Conclusions

Incidence of atrial fibrillation was 10.5 cases per 1000 person-years among a cohort of people with hypertension attending primary care. Age, sex, obesity and CHF were independently predictive of AF. We propose a simple risk score based on these four readily available variables, which enables the identification of people with hypertension who are at the greatest risk of AF, and subsequently the implementation of effective interventions to address modifiable risk factors.

Received: 22 July 2019; Accepted: 24 February 2020; Published: 16 March 2020

References

1. World Health Organization. World Health Organization Study: Atrial Fibrillation is a Growing Global Health Concern, https://www.who.int/news-room/fact-sheets/detail/atrial-fibrillation (Accessed 19 September 2017).
2. Naccarelli, G. V., Varker, H., Lin, J. & Schulman, K. L. Increasing prevalence of atrial fibrillation and flutter in the United States. Am J Cardiol. 104, 1534–1539 (2009).
3. Stefanadottir, H., Aspelin, T., Gudnason, V., Arnar, D.O. Trends in the incidence and prevalence of atrial fibrillation in Iceland and future projections. Europace. 13, 1110–1117 (2011), Ebup ahead print (2011).
4. Chugh, S.S. et al. Worldwide Epidemiology of Atrial Fibrillation: A Global Burden of Disease 2010 Study. Circulation. 129, 837–847 (2014), Ebup ahead print (2013).
5. Friberg, L., Bergfeldt, L. Atrial fibrillation prevalence revisited. J Intern Med. 274, 461–468 (2013), Ebup ahead print (2013).
6. Lobos-Bejarano, J. M. et al. On behalf of researchers of FIATE study. Caracteristicas de los pacientes y abordaje terapeutico de la fibrilacion auricular en atencion primaria en Espana: Estudio FIATE [Patients’ characteristics and clinical management of atrial fibrillation in primary healthcare in Spain: FIATE Study]. Med Clin (Barc). 141(7), 279–286 (2013).
7. Benjamin, E. J. et al. Independent risk factors for atrial fibrillation in a population-based cohort: The Framingham Heart Study. JAMA. 271, 840–844 (1994).
8. Wang, T. J. et al. Obesity and the risk of new-onset atrial fibrillation. JAMA. 292, 2471–2477 (2004).
9. Schnabel, R. B. et al. Development of a Risk Score for Atrial Fibrillation in the Community; The Framingham Heart Study. Lancet 373, 739–745 (2009).
10. Gami, A.S. et al. Obstructive sleep apnea, obesity, and the risk of incident atrial fibrillation. J Am Coll Cardiol 49, 565–571 (2007), Ebup ahead print (2007).
11. Ghiadoni, L., Taddei, S. & Virdis, A. Hypertension and Atrial Fibrillation: Any Change with the New Anticoagulants. Curr Pharm Des 20, 6096–6105 (2014).
12. Mills, K. T. et al. Global Disparities of Hypertension Prevalence and Control: A Systematic Analysis of Registry-Based Studies From 90 Countries. Circulation. 134, 441–450 (2016).
13. Arboix, A. et al. Importance of cardiovascular risk profile for in-hospital mortality due to cerebral infarction. Rev Esp Cardiol 61, 1020–1029 (2008).
14. Vangen-Lønne, A.M. et al. Declining Incidence of Ischemic Stroke. What Is the Impact of Changing Risk Factors? The Tromsø Study 1995 to 2012. Stroke 48, 544–550 (2017), Ebup ahead print (2017).
15. January, C. T. et al. ACC/AHA Task Force Members. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation. 130, 2071–2104 (2014), Ebup ahead print (2014).
16. Hart, R. G., Pearce, L. A. & Aguilar, M. I. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 146, 857–867 (2007).
17. Glotzer, T.V. et al. The relationship between daily atrial tachyarrhythmia burden from implantable device diagnostics and stroke risk: The TRENDS Study. Circulation. 2, 474–480 (2009), (Ebup ahead print) (2009).
18. Healey, J. S. et al. Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta- analysis. J Am Coll Cardiol 45, 1832–1839 (2005).
19. Verdecchia, P. et al. Atrial Fibrillation in Hypertension Predictors and Outcome. Hypertension. 41, 218–223 (2003).
20. Everett, B. M. et al. Novel genetic markers improve measures of atrial fibrillation risk prediction. Eur Heart J 34, 2243–2251 (2013), Ebup ahead print (2013).
21. Alonso, A. et al. Simple risk model predicts incidence of atrial fibrillation in a racially and geographically diverse population: the CHARGE-AF consortium. J Am Heart Assoc. 2, e001002 (2013).
22. Gil-Guillen, V. et al. Rationale and methods of the cardiometabolic Valencian study (Escarval-Risk) for validation of risk scales in Mediterranean patients with hypertension, diabetes or dyslipidemia. BMC Public Health. 10, 717 (2010).
23. Leyvey, A. S. et al. CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A New Equation to Estimate Glomerular Filtration Rate. Ann Intern Med. 150, 604–612 (2009).
24. National Institute for Health and Care Excellence. Atrial fibrillation: the management of atrial fibrillation. (Clinical guideline 180) 2014, http://guidance.nice.org (2014).
25. Sullivan, L. M., Massaro, J. M. & D’Agostino, R. B. Presentation of multivariate data for clinical use: the Framingham study risk score functions. Statistics in medicine. 23, 1631–1660 (2004).
26. Heeringa, J. et al. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J 27, 949–953 (2006).
27. Wilke, T. et al. Incidence and prevalence of atrial fibrillation: an analysis based on 8.3 million patients. Europace. 15, 486–493 (2013), Ebup ahead print (2012).
28. Kannel, W. B., Abbott, R. D., Savage, D. D. & McNamara, P. M. Epidemiologic Features of Chronic Atrial Fibrillation — The Framingham Study. N Engl J Med. 306, 1018–1012 (1982).
29. Alves-Cabratosa, L. et al. Statins and new-onset atrial fibrillation in a cohort of patients with hypertension. Analysis of electronic health records, 2006–2015. PloS One 12, e0186972 (2017).
30. Nalliah, C. J., Sanders, P., Kottkamp, H., Kalman, J. M. & Eur Heart J, The role of obesity in atrial fibrillation. Eur Heart J 37, 1565–1572 (2016).
31. Abed, H. S. et al. Effect of weight reduction and cardiometabolic risk factor management on symptom burden and severity in patients with atrial fibrillation: a randomized clinical trial. *JAMA*. **310**, 2050–2060 (2013).

32. Pathak, R.K. et al. Long-term effect of goal directed weight management in an atrial fibrillation cohort: a long-term follow-up study (LEGACY study). *J Am Coll Cardiol*. **65**, 2159–2169 (2015), Epub ahead print (2015).

33. Van Wagoner, D.R. et al. Progress toward the prevention and treatment of atrial fibrillation: A summary of the Heart Rhythm Society Research Forum on the Treatment and Prevention of Atrial Fibrillation, Washington, DC, December 9–10, 2013. *Heart rhythm: the official journal of the Heart Rhythm Society*. **12**, e65–e29, (2015), Epub ahead print (2014).

34. Gómez-Doblas, J.J. et al. en representación de los colaboradores del estudio OFRECE. Prevalencia de fibrilación auricular en España. Resultados del estudio OFRECE. Prevalence of atrial fibrillation is Spain. OFRECE Study. *Rev Esp Cardiol* **67**, 259–269 (2014).

35. Emdin, C.A., Callender, T., Cao, J., Rahimi, K. Effect of antihypertensive agents on risk of atrial fibrillation: a meta-analysis of large-scale randomized trials. *European Heart Journal*. **36**, 701–710 (2015), Epub ahead print (2015).

36. Okin, P.M. et al. Effect of lower on-treatment systolic blood pressure on the risk of atrial fibrillation in hypertensive patients. *Hypertension*. **66**, 368–73 (2015).

37. Nesbitt, S.D. Overcoming therapeutic inertia in patients with hypertension. *Postgrad Med*. **122**, 118–24 (2010), Epub ahead (2015).

38. Comín, E. et al. Estimating cardiovascular risk in Spain using different algorithms. *Rev Esp Cardiol*. **60**, 693–702 (2007).

**Acknowledgements**

This study was funded by the Spanish Ministry of Science and Innovation (MICINN) and Carlos III Health Institute (ISCIII)/European Regional Development Fund (ERDF), (RETICS: RD16/0007/0015). The authors declare no conflicts of interest.

**Author contributions**

J.M. L.B., D.O.B. and V.F.G.G. has contributed with the data collection, J.M.L.B., D.O.B., J.N.P., V.F.G.G. and V.B.G. conceived the study and aided in the design and execution. J.A.Q. did the statistical analysis. J.M. L.B., A.L.P., A.C.R., C.C.M. and V.B.G. contribute in the interpretation of the results and wrote the main text. A.C.R., A.L.D., AFJ.C.L. contribute in the preparation of the tables and figures. All authors provided support to all versions of the manuscript.

**Competing interests**

The authors declare no competing interests.

**Additional information**

Correspondence and requests for materials should be addressed to A.L.-P.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2020, corrected publication 2023